You are here

Trans‐nasal delivery of chemotherapy to glioblastoma using magnetic nanoparticles and magnetic focusing

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41CA213540-01A1
Agency Tracking Number: R41CA213540
Amount: $142,262.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: 102
Solicitation Number: PA16-303
Timeline
Solicitation Year: 2016
Award Year: 2017
Award Start Date (Proposal Award Date): 2017-06-01
Award End Date (Contract End Date): 2019-05-31
Small Business Information
5611 ROOSEVELT ST, Bethesda, MD, 20817-6739
DUNS: 809594661
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 STEVEN TOMS
 (216) 312-4992
 tomsstn1964@gmail.com
Business Contact
 IRVING WEINBERG
Phone: (301) 346-7944
Email: inweinberg@gmail.com
Research Institution
 RHODE ISLAND HOSPITAL
 593 EDDY STREET
PROVIDENCE, RI, 02903-4923
 Domestic nonprofit research organization
Abstract
Abstract Glioblastoma multiforme GBM is the deadliest form of brain tumor The current treatment includes a combination of surgical resection chemotherapy radiation and electrical disruption of mitosis has only extended survival to approximately to years Preliminary pre clinical findings suggest the potential effectiveness of the candidate drug cyclopamine However the drug is toxic to systemic stem cells when given intravenously and at high concentrations in the nervous system may cause toxicity to astrocytes Furthermore poor solubility has precluded effective transport of drug to tumor in the central nervous system The Molecular Neurosurgery Laboratory led by the STTR PI neurosurgeon Dr Steven Toms at the Geisinger Medical Center has expertise in nanoparticulate delivery to brain tumors and has developed a human glioblastoma stem cell derived xenograft model for in vitro and in vivo testing of therapies for GBM STTR applicant Weinberg Medical Physics LLC has developed a new method of transporting drug across the blood brain barrier directly to target sites within the brain This approach accesses the brain via administration of magnetically propelled nanoparticles into the cranium with magnetic focusing of the drug laden nanoparticles in a novel combined MR imaging magnetic focusing apparatus In this proposal we will demonstrate the safety and efficacy of drug delivery of the magnetic nanoparticle cyclopamine construct using the MR imaging magnetic focusing apparatus by measuring cyclopamine drug concentrations in animal tissues In addition we will confirm that there are no neuropathological changes to the animals as a result of the magnetic propulsion process and demonstrate that this method of drug delivery improves survival in rodent GBM xenograft models The results of this collaborative work will lay the foundation for Phase II studies that will collect information needed for clinical trials STTR applicant Weinberg Medical Physics LLC has developed a new method of transporting drug across the blood brain barrier directly to target sites within the brain This approach accesses the brain via trans nasal administration of magnetically propelled nanoparticles and then magnetically focuses the drug laden nanoparticles in a novel combined MR imaging magnetic focusing apparatus In this proposal we will demonstrate the safety and efficacy of drug delivery of the magnetic nanoparticle cyclopamine construct using the MR imaging magnetic focusing apparatus by measuring cyclopamine drug concentrations in animal tissues

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government